Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more
Y mAbs Therapeutics (YMAB) - Net Assets
Latest net assets as of June 2025: $87.49 Million USD
Based on the latest financial reports, Y mAbs Therapeutics (YMAB) has net assets worth $87.49 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($117.21 Million) and total liabilities ($29.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $87.49 Million |
| % of Total Assets | 74.65% |
| Annual Growth Rate | 28.91% |
| 5-Year Change | -13.07% |
| 10-Year Change | N/A |
| Growth Volatility | 193.2 |
Y mAbs Therapeutics - Net Assets Trend (2016–2024)
This chart illustrates how Y mAbs Therapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Y mAbs Therapeutics (2016–2024)
The table below shows the annual net assets of Y mAbs Therapeutics from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $92.00 Million | -8.89% |
| 2023-12-31 | $100.98 Million | -7.54% |
| 2022-12-31 | $109.22 Million | -39.36% |
| 2021-12-31 | $180.11 Million | +70.17% |
| 2020-12-31 | $105.84 Million | -46.79% |
| 2019-12-31 | $198.90 Million | +41.54% |
| 2018-12-31 | $140.53 Million | +71.06% |
| 2017-12-31 | $82.15 Million | +581.14% |
| 2016-12-31 | $12.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Y mAbs Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46473600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $2.26 Million | 2.46% |
| Other Components | $576.87 Million | 627.01% |
| Total Equity | $92.00 Million | 100.00% |
Y mAbs Therapeutics Competitors by Market Cap
The table below lists competitors of Y mAbs Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Peoples Bancorp of North Carolina
NASDAQ:PEBK
|
$162.70 Million |
|
Dynamix Corporation Unit
NASDAQ:DYNXU
|
$162.78 Million |
|
Nihon Chouzai Co.Ltd
PINK:NHCZF
|
$162.79 Million |
|
Tederic Machinery Co Ltd
SHG:603289
|
$162.83 Million |
|
Analog Integrations Corporation
TWO:6291
|
$162.63 Million |
|
Isik Plastik Sanayi ve Dis Ticaret Pazarlama AS
IS:ISKPL
|
$162.62 Million |
|
Oriental Kopi Holdings Berhad
KLSE:0338
|
$162.62 Million |
|
Taiwan Fu Hsing Industrial Co Ltd
TW:9924
|
$162.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Y mAbs Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 100,985,000 to 92,004,000, a change of -8,981,000 (-8.9%).
- Net loss of 29,666,000 reduced equity.
- Other comprehensive income increased equity by 1,815,000.
- Other factors increased equity by 18,870,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.67 Million | -32.24% |
| Other Comprehensive Income | $1.81 Million | +1.97% |
| Other Changes | $18.87 Million | +20.51% |
| Total Change | $- | -8.89% |
Book Value vs Market Value Analysis
This analysis compares Y mAbs Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.60x to 4.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.68 | $8.61 | x |
| 2017-12-31 | $2.47 | $8.61 | x |
| 2018-12-31 | $4.88 | $8.61 | x |
| 2019-12-31 | $5.65 | $8.61 | x |
| 2020-12-31 | $2.64 | $8.61 | x |
| 2021-12-31 | $4.17 | $8.61 | x |
| 2022-12-31 | $2.50 | $8.61 | x |
| 2023-12-31 | $2.31 | $8.61 | x |
| 2024-12-31 | $2.08 | $8.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Y mAbs Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.83%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.30x
- Recent ROE (-32.24%) is above the historical average (-57.88%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -141.42% | 0.00% | 0.00x | 1.43x | $-18.26 Million |
| 2017 | -23.32% | 0.00% | 0.00x | 1.12x | $-27.38 Million |
| 2018 | -30.79% | 0.00% | 0.00x | 1.08x | $-57.33 Million |
| 2019 | -39.66% | 0.00% | 0.00x | 1.09x | $-98.78 Million |
| 2020 | -112.76% | -575.12% | 0.16x | 1.25x | $-129.92 Million |
| 2021 | -31.28% | -161.46% | 0.16x | 1.18x | $-74.36 Million |
| 2022 | -88.19% | -147.59% | 0.46x | 1.30x | $-107.25 Million |
| 2023 | -21.22% | -25.26% | 0.66x | 1.27x | $-31.53 Million |
| 2024 | -32.24% | -33.83% | 0.73x | 1.30x | $-38.87 Million |
Industry Comparison
This section compares Y mAbs Therapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Y mAbs Therapeutics (YMAB) | $87.49 Million | -141.42% | 0.34x | $162.66 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |